ONE-CARBON THERAPEUTICS

Our primary targets are MTHFD1/2 isoenzyme proteins that regulate one-carbon metabolism, often upregulated in multiple cancers. MTHFD2 is an oncofoetal protein expressed during embryogenesis, silenced in normal adult cells, and then re-expressed in cancer. Both proteins have been validated as anti-cancer targets by numerous independent laboratories. We are proud to have made a first-in-class, low nanomolar potent inhibitor of MTHFD1/2 for clinical development using state-of-the-art structural and medicinal chemistry approaches... At One-carbon therapeutics we apply cutting-edge science to create first-in-class treatments against MTHFD1/2 cancer proteins and related targets. Our development is guided by advanced biomarkers identified using primary cancer patient's tumors... Co-founded in 2020 by the Helleday Laboratory, with over 20 years of experience in DNA damage response (DDR) biology, we are taking the previous success of discovering the synthetic lethal concept for the treatment..

Also known as: one-carbon, One-carbon Therapeutics AB

Primary location: Stockholm Sweden